Query author contributions in Reactome
Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.
If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.
Details on Person Interleukin-10 (IL10) was originally described as a factor n...
| Class:Id | Summation:6783737 |
|---|---|
| _displayName | Interleukin-10 (IL10) was originally described as a factor n... |
| _timestamp | 2016-09-05 11:16:59 |
| created | [InstanceEdit:6783726] Jupe, Steve, 2015-06-17 |
| literatureReference | [LiteratureReference:6783760] Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones [LiteratureReference:6783747] Interleukin-10 and the interleukin-10 receptor [LiteratureReference:6783779] Interleukin-10 and related cytokines and receptors [LiteratureReference:6783717] The multifaceted relationship between IL-10 and adaptive immunity: putting together the pieces of a puzzle [LiteratureReference:6783764] Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes [LiteratureReference:6783749] IL-10 inhibits parasite killing and nitrogen oxide production by IFN-gamma-activated macrophages [LiteratureReference:6783716] IL-10, T lymphocyte inhibitor of human blood cell production of IL-1 and tumor necrosis factor [LiteratureReference:6783721] Direct effects of IL-10 on subsets of human CD4+ T cell clones and resting T cells. Specific inhibition of IL-2 production and proliferation [LiteratureReference:6783736] Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes [LiteratureReference:6783738] Interleukin 10: a novel stimulatory factor for mast cells and their progenitors [LiteratureReference:6783789] Continuous anti-interleukin 10 antibody administration depletes mice of Ly-1 B cells but not conventional B cells [LiteratureReference:6783763] Modified immunological status of anti-IL-10 treated mice [LiteratureReference:6783791] Interleukin 10 (IL-10) inhibits human lymphocyte interferon gamma-production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells [LiteratureReference:6783755] IL-10 inhibits cytokine production by activated macrophages [LiteratureReference:6783751] Interleukin-10-deficient mice develop chronic enterocolitis [LiteratureReference:6783743] Interleukin 10 but not interleukin 4 is a natural suppressant of cutaneous inflammatory responses [LiteratureReference:6784355] Infection-induced IL-10 and JAK-STAT: A review of the molecular circuitry controlling immune hyperactivity in response to pathogenic microbes [LiteratureReference:6783770] Cell type-specific regulation of IL-10 expression in inflammation and disease [LiteratureReference:6783773] IL-10 enhances NK cell proliferation, cytotoxicity and production of IFN-gamma when combined with IL-18 [LiteratureReference:6784326] The interleukin-10 signal transduction pathway and regulation of gene expression in mononuclear phagocytes [LiteratureReference:6784320] Differential IL-10R1 expression plays a critical role in IL-10-mediated immune regulation [LiteratureReference:449813] Identification and functional characterization of a second chain of the interleukin-10 receptor complex [LiteratureReference:6784351] JAK2 activation by growth hormone and other cytokines [LiteratureReference:6784349] Conformational changes mediate interleukin-10 receptor 2 (IL-10R2) binding to IL-10 and assembly of the signaling complex |
| modified | [InstanceEdit:6783804] Jupe, Steve, 2015-06-17 [InstanceEdit:6784364] Jupe, Steve, 2015-06-19 [InstanceEdit:6785740] Jassal, Bijay, 2015-07-01 [InstanceEdit:8878400] Jupe, Steve, 2016-07-04 [InstanceEdit:8937645] Jupe, Steve, 2016-09-05 |
| text | Interleukin-10 (IL10) was originally described as a factor named cytokine synthesis inhibitory factor that inhibited T-helper (Th) 1 activation and Th1 cytokine production (Fiorentino et al. 1989). It was found to be expressed by a variety of cell types including macrophages, dendritic cell subsets, B cells, several T-cell subpopulations including Th2 and T-regulatory cells (Tregs) and Natural Killer (NK) cells (Moore et al. 2001). It is now recognized that the biological effects of IL10 are directed at antigen-presenting cells (APCs) such as macrophages and dendritic cells (DCs), its effects on T-cell development and differentiation are largely indirect via inhibition of macrophage/dendritic cell activation and maturation (Pestka et al. 2004, Mocellin et al. 2004). T cells are thought to be the main source of IL10 (Hedrich & Bream 2010). IL10 inhibits a broad spectrum of activated macrophage/monocyte functions including monokine synthesis, NO production, and expression of class II MHC and costimulatory molecules such as IL12 and CD80/CD86 (de Waal Malefyt et al. 1991, Gazzinelli et al. 1992). Studies with recombinant cytokine and neutralizing antibodies revealed pleiotropic activities of IL10 on B, T, and mast cells (de Waal Malefyt et al. 1993, Rousset et al. 1992, Thompson-Snipes et al. 1991) and provided evidence for the in vivo significance of IL10 activities (Ishida et al. 1992, 1993). IL10 antagonizes the expression of MHC class II and the co-stimulatory molecules CD80/CD86 as well as the pro-inflammatory cytokines IL1Beta, IL6, IL8, TNFalpha and especially IL12 (Fiorentino et al. 1991, D'Andrea et al. 1993). The biological role of IL10 is not limited to inactivation of APCs, it also enhances B cell, granulocyte, mast cell, and keratinocyte growth/differentiation, as well as NK-cell and CD8+ cytotoxic T-cell activation (Moore et al. 2001, Hedrich & Bream 2010). IL10 also enhances NK-cell proliferation and/or production of IFN-gamma (Cai et al. 1999). IL10-deficient mice exhibited inflammatory bowel disease (IBD) and other exaggerated inflammatory responses (Kuhn et al. 1993, Berg et al. 1995) indicating a critical role for IL10 in limiting inflammatory responses. Dysregulation of IL10 is linked with susceptibility to numerous infectious and autoimmune diseases in humans and mouse models (Hedrich & Bream 2010). IL10 signaling is initiated by binding of homodimeric IL10 to the extracellular domains of two adjoining IL10RA molecules. This tetramer then binds two IL10RB chains. IL10RB cannot bind to IL10 unless bound to IL10RA (Ding et al. 2001, Yoon et al. 2006); binding of IL10 to IL10RA without the co-presence of IL10RB fails to initiate signal transduction (Kotenko et al. 1997). IL10 binding activates the receptor-associated Janus tyrosine kinases, JAK1 and TYK2, which are constitutively bound to IL10R1 and IL10R2 respectively. In the classic model of receptor activation assembly of the receptor complex is believed to enable JAK1/TYK2 to phosphorylate and activate each other. Alternatively the binding of IL10 may cause conformational changes that allow the pseudokinase inhibitory domain of one JAK kinase to move away from the kinase domain of the other JAK within the receptor dimer-JAK complex, allowing the two kinase domains to interact and trans-activate (Waters & Brooks 2015). The activated JAK kinases phosphorylate the intracellular domains of the IL10R1 chains on specific tyrosine residues. These phosphorylated tyrosine residues and their flanking peptide sequences serve as temporary docking sites for the latent, cytosolic, transcription factor, STAT3. STAT3 transiently docks on the IL10R1 chain via its SH2 domain, and is in turn tyrosine phosphorylated by the receptor-associated JAKs. Once activated, it dissociates from the receptor, dimerizes with other STAT3 molecules, and translocates to the nucleus where it binds with high affinity to STAT-binding elements (SBEs) in the promoters of IL-10-inducible genes (Donnelly et al. 1999). |
| (summation) | [Pathway:6783783] Interleukin-10 signaling [Homo sapiens] |
| [Change default viewing format] | |
No pathways have been reviewed or authored by Interleukin-10 (IL10) was originally described as a factor n... (6783737)
